Symbiotix Biotherapies Raises Equity Round from Kairos Ventures

Press Release

 | November 2, 2017

Choate recently represented Symbiotix Biotherapies, Inc. (Symbiotix), a pioneering microbiome company developing novel molecular therapeutics based on the human microbiome, in its recent equity financing from Kairos Ventures, LLC.

Symbiotix is a pioneering microbiome company founded on the basis of over two decades of research at Brigham & Women’s Hospital/Harvard Medical School, California Institute of Technology and Dartmouth College. Symbiotix is developing a novel class of Treg-modulating therapeutics based on molecules derived from the human microbiome.

Choate has represented Symbiotix since its formation. The transactional team was led by Brian Goldstein and Tobin Sullivan and ongoing IP strategy for the company has been led by Dr. Brenda Herschbach Jarrell.


Thank you for reaching out to contact Choate. Before you send your message, we wanted to make sure you are aware of the following. Please do not send any confidential information in response to this link. Sending an e-mail to Choate does not give rise to an attorney-client relationship, and will not be deemed to disqualify Choate from undertaking any engagement for a current or future client.  Before any attorney-client engagement may be formed, Choate will need to check for possible conflicts of interest, you will need to consider whether you wish to retain Choate as counsel, and we will need to consider whether we wish to accept the potential engagement. In the meantime, Choate reserves the right to represent parties with interests adverse to you.